Gustavo Henrique Santos Pereira

I am a gastroenterologist and hepatologist with a career that integrates clinical practice, teaching, and research. I graduated in Medicine from the Federal University of Rio de Janeiro (UFRJ) and completed a residency in Gastroenterology at UERJ. My international training includes a Master in Research in Liver Disease and a PhD in Medicine from the University of Barcelona, along with advanced training in Liver Transplantation at the University of Miami and certifications in Internal Medicine Ultrasound and Elastography.
I serve as Adjunct Professor at Universidade Estácio de Sá (UNESA) and collaborating faculty member of the Graduate Program in Clinical Medicine at UFRJ. Clinically, I work at the Gastroenterology and Hepatology Service of the Federal Hospital of Bonsucesso, where I previously held the positions of service chief and residency program coordinator. My main research interests include cirrhosis, acute-on-chronic liver failure, portal hypertension, MASLD, viral hepatitis, c

EDUCATION

MD, Universidade Federal do Rio de Janeiro (UFRJ); Residency in Gastroenterology, UERJ; MSc in Liver Disease, University of Barcelona; PhD in Medicine, University of Barcelona; Advanced Training in Liver Transplantation, University of Miami.

RESEARCH, TEACHING, or OTHER INTERESTS

Hepatology, Gastroenterology, Nephrology, Oncology

FUTURE PROJECTS

Scopus Publications

Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome
Ann T. Ma, Adrià Juanola, Kavish R. Patidar, Anna Barone, Simone Incicco, et al.
Clinical Gastroenterology and Hepatology, 2026
Liver Failure, Hepatic Encephalopathy, and Infection Contribute to Mortality Risk in a Global Cirrhosis Cohort
Jasmohan S. Bajaj, Scott Silvey, Aidan Mullan, Ashok Choudhury, Florence Wong, et al.
Clinical Gastroenterology and Hepatology, 2026
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
Scott Silvey, Ashok K. Choudhury, Patrick S. Kamath, Qing Xie, Florence Wong, et al.
American Journal of Gastroenterology, 2026
INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
Transient elastography and fibrosis-4 index as predictors of hepatocellular carcinoma in hepatitis C virus patients with sustained virological response
Paula G F da Silva, Juliana B P Barrocas, Hugo Perazzo, Livia Villela-Nogueira, Helena R Peixoto, et al.
World Journal of Gastroenterology, 2025
BACKGROUND People with compensated advanced chronic liver disease (cACLD) remain at high risk of hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) sustained virological response (HCV-SVR). AIM To evaluate transient elastography and fibrosis-4 (FIB-4) index as prognostic markers for HCC after HCV-SVR. METHODS This retrospective cohort study analyzed data from people with cALCD and HCV-SVR. cALCD was defined as baseline liver stiffness measurement (LSM) ≥ 10 kPa. The primary outcome was the occurrence of HCC. Data collected at baseline (pre-treatment) and 1 year after the end of treatment (1-year-EOT) of LSM, FIB-4 index, and laboratory results were analyzed. LSM and FIB-4 index were evaluated as independent predictors of HCC by a Cox regression analysis. Receiver operator characteristic curves, Kaplan-Meier curves, and Cox regression analysis were performed. RESULTS Total of 425 patients (65.2% female; mean age = 62 ± 10 years) were included. The median pre-treatment and 1-year-EOT LSM were respectively 15.0 kPa (interquartile range: 11.8-23.2) and 12 kPa (interquartile range: 7.9-19.9) (P < 0.001), with a 27% (interquartile range: 2.7%-43%) reduction after SVR. The median pre-treatment FIB-4 index was 2.94 (interquartile range: 1.89-4.85) and 1-year-EOT FIB-4 1.99 (interquartile range: 1.29-3.13) (P < 0.001). Neither LSM nor FIB-4 deltas were associated with HCC. A total of 26 participants (6%) developed HCC during a follow-up of 48 ± 23 months with an incidence of 15.3/1000 person-years. Age [hazard ratio (HR) = 1.06, 95% confidence interval (CI): 1.01-1.11; P = 0.02], baseline (HR = 1.05, 95%CI: 1.02-1.07) and 1-year-EOT LSM ≥ 20 kPa (HR = 4.49, 95%CI: 2.19-9.19; P < 0.001) and baseline (HR = 7.79, 95%CI: 2.31-26.32; P < 0.001) and 1-year-EOT FIB-4 index score ≥ 3.25 (HR = 3.14, 95%CI: 1.65-6.00; P < 0.001) were associated with incident HCC. CONCLUSION In cACLD-HCV SVR patients, pre-treatment or 1-year-EOT LSM ≥ 20 kPa and FIB-4 ≥ 3.25 but not their delta was associated with HCC. A single measure of LSM ≥ 20 kPa or FIB-4 ≥ 3.25, either pre-treatment or 1-year-EOT, would be necessary to predict the incidence of HCC in people with HCV-SVR.
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
Ângelo Z. Mattos, Caroline Machado Rotta Dornelles, Leonardo de Lucca Schiavon, Liliana Sampaio Costa Mendes, Roberto José de Carvalho Filho, et al.
Hepatology International, 2025
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis
Jonel Trebicka, Ferran Aguilar, Alberto Queiroz Farias, Juan-José Lozano, Cristina Sánchez-Garrido, et al.
Gut, 2025
Background and aimsQuantifying systemic inflammation (SI) in acutely decompensated cirrhosis (ADC) is of major importance because SI is a driver of the most severe forms of ADC, including acute-on-chronic liver failure (ACLF). Blood biomarkers of SI already evaluated in ADC failed to appropriately assess SI in ADC. We aimed to investigate whether gene expression related to circulating immune cells could quantify SI in ADC.MethodsStandard biomarkers (white cell count, C reactive protein, cytokines) and genome-wide RNA expression (RNA-sequencing) were obtained in blood from 700 patients with ADC at the time of their hospital admission. A composite score based on standard biomarkers of SI (Chronic Liver Failure-Standard Biomarkers Composite (CLIF-SBC) score) and a gene score (CLIF-Systemic Inflammation Gene (SIG) score) composed of the 28 top differentially expressed immune cell-related genes in the comparison between high-severity and low-severity clinical phenotypes were computed. Among the 700 patients, the CLIF-SIG score was repeated once during follow-up in 375 patients, and 3 times or more in 46 patients.ResultsThe CLIF-SIG score was more accurate in reflecting clinical severity induced by SI than the CLIF-SBC score (area under the curve 0.803 vs 0.658). A CLIF-SIG score of 0.386 (Youden Index) was the best cut-off level discriminating patients with poor outcomes from the others, in all clinical scenarios. Sequential measurement of the CLIF-SIG score showed that 78% of patients were admitted at the peak or descending part of the SI-wave. ACLF developed during hospitalisation in 80% of patients with a CLIF-SIG score >0.386 on admission.ConclusionsIn patients with ADC, the CLIF-SIG score is an accurate estimator of SI, clinical course severity and prognosis.
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study
Kavish R Patidar, Ann T Ma, Adrià Juanola, Anna Barone, Simone Incicco, et al.
Lancet Gastroenterology and Hepatology, 2025
Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis
Camila Marques de Alcântara Barreto, Eliane Almeida do Valle, Jessica Pronestino de Lima Moreira, Katia Farias e Silva, Siane Lopes Bittencourt Rosas, et al.
Annals of Hepatology, 2025
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
Zhujun Cao, Florence Wong, Ashok K Choudhury, Patrick S Kamath, Mark Topazian, et al.
Lancet Gastroenterology and Hepatology, 2024
Retrieval of HCV patients lost to follow-up as a strategy for Hepatitis C Microelimination: results of a Brazilian multicentre study
Maria Lucia Gomes Ferraz, Antonio Ricardo Cardia Ferraz de Andrade, Gustavo Henrique Santos Pereira, Liana Codes, Paulo Lisboa Bittencourt
BMC Infectious Diseases, 2023
BackgroundSeveral HCV patients in Brazil were lost to follow-up (LTFU) in the last two decades before achievement of sustained virological response (SVR). Strategies to recall those diagnosed but untreated patients have been used elsewhere with different success rates.AimTo identify and retrieve LTFU patients in order to offer them the treatment with the current highly effective direct acting antiviral agents (DAAs).MethodsRegistries ofall HCV patients from three large reference centers in Brazil were retrospectively reviewed to identify those with no registry of SVR. Reasons for non-achievement of SVR were elicited in HCV-RNA + patients. All patients who were not treated or cured were contacted to offer the therapy with DAAs.Results10,289 HCV patients (50% males, mean age 52 ± 11 years) were identified. Only 4,293 (41.7%) had been successfully treated previously. From the remaining 5,996 most were LTFU (59%), were not treated for other reasons (14.7%) or were non-responders (26.3%). After revision of the charts 3,559 were considered eligible to be retrieved. The callback success of phone calls was 18%, 13% to cellphone messages (SMS or WhatsApp) and 7% to regular mail. Five-hundred sixty patients had been already treatedor were on treatment and 234 were reported to be dead or transplanted. Finally, 201 had made an appointment and initiated antiviral treatment.ConclusionEven considering the low callback rate, retrieval of LTFU patients was shown to be an important strategy forhepatitis C micro-elimination in Brazil.
Severe thrombocytopenia in cirrhotic patients treated with Piperacillin-Tazobactam
Lívia Guimarães, Juliana Piedade, Tamires Rocha, Caroline Baldin, Lívia Victor, et al.
Journal of Liver Transplantation, 2023
Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study
Nicolas M. Intagliata, Robert S. Rahimi, Fatima Higuera-de-la-Tijera, Douglas A. Simonetto, Alberto Queiroz Farias, et al.
Gastroenterology, 2023
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America
Alberto Queiroz Farias, Anna Curto Vilalta, Patricia Momoyo Zitelli, Gustavo Pereira, Luciana L. Goncalves, et al.
Gastroenterology, 2023
Hepatic Encephalopathy in Cirrhotic Patients With Bacterial Infections: Frequency, Clinical Characteristics, and Prognostic Relevance
Lívia Guimarães, Juliana Piedade, Joana Duarte, Caroline Baldin, Lívia Victor, et al.
Journal of Clinical and Experimental Hepatology, 2023
Validation of the Baveno VI criteria to rule out high-risk varices using hepatic shear-wave elastography
Élio C. Castro Filho, Flávia F. Fernandes, Cristiane Villela-Nogueira, Eduardo Madeira, Fernando Barros, et al.
European Journal of Gastroenterology and Hepatology, 2023
Accuracy and concordance of two-dimensional shear-wave elastography using transient elastography as the reference in chronic viral hepatitis and HIV infection in Rio de Janeiro, Brazil
Mariana Coelho, Flavia Fernandes, Sandra W. Cardoso, Juliana Piedade, Marcos Vinícius Torres da Silva, et al.
European Journal of Gastroenterology and Hepatology, 2023
Natural History of Hepatosplenic Schistosomiasis (HSS) Non–Cirrhotic Portal Hypertension (NCPH): Influence of Gastrointestinal Bleeding and Decompensation in Prognosis
Zulane S. T. Veiga, Flávia F. Fernandes, Lívia Guimarães, Juliana Piedade, Gustavo Henrique S. Pereira
Tropical Medicine and Infectious Disease, 2023
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort
Lívia Victor, Renata Perez, Flávia Fernandes, Juliana Piedade, Cristiane A. Villela-Nogueira, et al.
Medicine United States, 2022
Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
Gustavo H. Pereira, Helena R. Peixoto, Mariana L. Giusti, Mariana L. Souza, Livia B. Victor, et al.
Brazilian Journal of Infectious Diseases, 2022
Agreement and accuracy of shear-wave techniques (point shear-wave elastography and 2D-shear-wave elastography) using transient elastography as reference
Flavia Fernandes, Juliana Piedade, Gabriela Freitas, Philippe Area, Ricardo Santos, et al.
European Journal of Gastroenterology and Hepatology, 2022
National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
Maria Lúcia Gomes Ferraz, Leonora de Zorzi Piccoli, Rosamar Rezende, Luiz Augusto Borba, Alcindo Pissaia Junior, et al.
Brazilian Journal of Infectious Diseases, 2022
Liver Growth and Portal Hypertension Improvement After Percutaneous Recanalization of Chronic Portal Vein Thrombosis in Non-Cirrhotic Participants
Raphael Braz Levigard, Henrique Salas, Henrique Serrão, Felipe Diniz, Cristiane Alves Villela Nogueira, et al.
Cardiovascular and Interventional Radiology, 2022
Noninvasive predictors of esophageal varices in patients with hepatosplenic schistosomiasis mansoni
Mateus Jorge Nardelli, Zulane da Silva Tavares Veiga, Luciana Costa Faria, Gustavo Henrique Santos Pereira, Catherine Ferreira da Silva, et al.
Acta Tropica, 2022
CLIF-C AD Score Predicts Development of Acute Decompensations and Survival in Hospitalized Cirrhotic Patients
Caroline Baldin, Juliana Piedade, Lívia Guimarães, Lívia Victor, Joana Duarte, et al.
Digestive Diseases and Sciences, 2021
Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
Juliana Piedade, Gustavo Pereira, Lívia Guimarães, Joana Duarte, Lívia Victor, et al.
Scientific Reports, 2021
COVID-19 in liver transplant recipients
Juliana Piedade, Gustavo Pereira
Journal of Liver Transplantation, 2021
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, Jean-Charles Nault, Gonzalo Sapisochin, et al.
Jhep Reports, 2021
2-D shear wave elastography for the evaluation of liver fibrosis in hepatosplenic schistosomiasis: Reliability of a single measurement and inter-hepatic lobe variability
Zulane S. T. Veiga, Hugo Perazzo, Flávia F. Fernandes, Gustavo H. Pereira, Marta G. Cavalcanti, et al.
American Journal of Tropical Medicine and Hygiene, 2021
Systemic Inflammatory Response Syndrome in Patients Hospitalized for Acute Decompensation of Cirrhosis
Ariane Borgonovo, Caroline Baldin, Dariana C. Maggi, Livia Victor, Emilia T. O. Bansho, et al.
Canadian Journal of Gastroenterology and Hepatology, 2021
Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: A systematic review and meta-analysis
Elio C. Castro Filho, Juliana Piedade, Rodolfo Castro, Paula M. Luz, Flavia Fernandes, et al.
Journal of Viral Hepatitis, 2020
COVID-19: An Overview of Worldwide Recommendations for Management of Patients With Liver Diseases or Liver Transplantation
Hugo Perazzo, Juliana Piedade, Rodolfo Castro, Laura Pinto, Valdiléa G. Veloso, et al.
Clinical Gastroenterology and Hepatology, 2020
Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies
Elio C. Castro Filho, Rodolfo Castro, Flavia F. Fernandes, Gustavo Pereira, Hugo Perazzo
Gastrointestinal Endoscopy, 2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Álvaro Díaz‐González, Marco Sanduzzi‐Zamparelli, Leonardo G. da Fonseca, Giovan G. Di Costanzo, Rogerio Alves, et al.
Liver International, 2020
Combination and sequential evaluation of acute-on-chronic liver failure (ACLF) and hyponatremia and prognosis in cirrhotic patients
Gustavo Pereira, Caroline Baldin, Juliana Piedade, Vanessa Reis, Tatiana Valdeolivas, et al.
Digestive and Liver Disease, 2020
Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response
Flavia F Fernandes, Juliana Piedade, Livia Guimaraes, Estevao P Nunes, Ursula Chaves, et al.
Journal of Gastroenterology and Hepatology Australia, 2019
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil
Cirley Maria de Oliveira Lobato, Liana Codes, Giovanni Faria Silva, Aécio Flávio Meirelles Souza, Henrique Sérgio Moraes Coelho, et al.
Annals of Hepatology, 2019
Recommendations for invasive procedures in patients with diseases of the liver and biliary tract: Report of a joint meeting of the brazilian society of hepatology (SBH), brazilian society of digestive endoscopy (SOBED) and brazilian society of interventional radiology and endovascular surgery (SOBRICE)
Leonardo de Lucca SCHIAVON, Flávio Hayato EJIMA, Marcos Roberto de MENEZES, Paulo Lisboa BITTENCOURT, Aírton Mota MOREIRA, et al.
Arquivos De Gastroenterologia, 2019
Recommendations of the Brazilian society of hepatology for the management of acute kidney injury in patients with cirrhosis
Carlos TERRA, Ângelo Zambam de MATTOS, Gustavo PEREIRA, Alberto Queiroz FARIAS, Mario KONDO, et al.
Arquivos De Gastroenterologia, 2018
Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard
Flavia F. Fernandes, Hugo Perazzo, Luiz E. Andrade, Alessandra Dellavance, Carlos Terra, et al.
Biomed Research International, 2017
Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis
Zulane S.T. Veiga, Cristiane A. Villela-Nogueira, Flávia F. Fernandes, Marta G. Cavalcanti, Fátima A. Figueiredo, et al.
European Journal of Gastroenterology and Hepatology, 2017
Intensive care management of patients with liver disease: Proceedings of a single-topic conference sponsored by the brazilian society of hepatology
Paulo Lisboa Bittencourt, Carlos Terra, Edison Roberto Parise, Alberto Queiroz Farias, Vincent Arroyo, et al.
Arquivos De Gastroenterologia, 2015
The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure
Rajiv Jalan, Marco Pavesi, Faouzi Saliba, Alex Amorós, Javier Fernandez, et al.
Journal of Hepatology, 2015
Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients
Flavia F. Fernandes, Maria L. Ferraz, Luiz E. Andrade, Alessandra Dellavance, Carlos Terra, et al.
Journal of Clinical Gastroenterology, 2015
Reply to: Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C
Zulane Veiga, Gustavo H.S. Pereira, Flávia F. Fernandes, Daniela M. Mariz, João L. Pereira
European Journal of Gastroenterology and Hepatology, 2014
Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival
Rogelio Barreto, Claudia Fagundes, Mónica Guevara, Elsa Solà, Gustavo Pereira, et al.
Hepatology, 2014
Erratum: Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis" [J Hepatol 2014; 60: 955-961]
Ezequiel Rodríguez, Chiara Elia, Elsa Solà, Rogelio Barreto, Isabel Graupera, et al.
Journal of Hepatology, 2014
Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis
Ezequiel Rodríguez, Chiara Elia, Elsa Solà, Rogelio Barreto, Isabel Graupera, et al.
Journal of Hepatology, 2014
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study
Macarena Simón-Talero, Rita García-Martínez, Maria Torrens, Salvador Augustin, Susana Gómez, et al.
Journal of Hepatology, 2013
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis
Claudia Fagundes, Rogelio Barreto, Mónica Guevara, Elisabet Garcia, Elsa Solà, et al.
Journal of Hepatology, 2013
Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis
Claudia Fagundes, Marie-Noëlle Pépin, Mónica Guevara, Rogelio Barreto, Gregori Casals, et al.
Journal of Hepatology, 2012
Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study
Gustavo Pereira, Mónica Guevara, Claudia Fagundes, Elsa Solá, Ezequiel Rodríguez, et al.
Journal of Hepatology, 2012
Spontaneous bacterial peritonitis
European Gastroenterology and Hepatology Review, 2012
Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis
José Altamirano, Claudia Fagundes, Marlene Dominguez, Elisabet García, Javier Michelena, et al.
Clinical Gastroenterology and Hepatology, 2012
Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy
Mónica Guevara, María E. Baccaro, Beatriz Gómez-Ansón, Giovanni Frisoni, Cristina Testa, et al.
Journal of Hepatology, 2011
Prognostic importance of the cause of renal failure in patients with cirrhosis
Marta Martín–Llahí, Mónica Guevara, Aldo Torre, Claudia Fagundes, Tea Restuccia, et al.
Gastroenterology, 2011
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension
Elsa Solà, Sabela Lens, Mónica Guevara, Marta Martín-Llahí, Claudia Fagundes, et al.
Hepatology, 2010
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
André Nazar, Gustavo Henrique Pereira, Mónica Guevara, Marta Martín-Llahi, Marie-Noëlle Pepin, et al.
Hepatology, 2010

RECENT SCHOLAR PUBLICATIONS

1183 ACTIVE CANNABIS USE IS A POTENT INDEPENDENT PREDICTOR OF MORTALITY IN ALCOHOL-ASSOCIATED HEPATITIS: A MULTINATIONAL COMPETING-RISK ANALYSIS
OA ALBHAISI, F Idalsoaga, W Wang, JP Arab, LA Diaz, AJ Sanyal, ...
Gastrointestinal Endoscopy 103 (5), S-1414 , 2026
2026
IMPACTO DE LAS INFECCIONES BACTERIANAS EN PACIENTES CON CIRROSIS DESCOMPENSADA E INSUFICIENCIA RENAL AGUDA. UN SUBANÁLISIS DEL ICA-AKI GLOBAL STUDY
MJ Moreta, A Juanola, KR Patidar, AT Ma, A Barone, S Incicco, ...
Gastroenterología y Hepatología 49, 113164 , 2026
2026
Impact of non-selective beta-blockers on acute kidney injury outcomes in decompensated cirrhosis
S Incicco, KR Patidar, A Juanola, AT Ma, A Barone, AV Kulkarni, ...
Digestive and Liver Disease 58, S22-S23 , 2026
2026
Transient elastography and fibrosis-4 index as predictors of hepatocellular carcinoma in hepatitis C virus patients with sustained virological response
PGF da Silva, JBP Barrocas, H Perazzo, L Villela-Nogueira, HR Peixoto, ...
World Journal of Gastroenterology 31 (45), 112318 , 2025
2025
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study
ÂZ Mattos, CMR Dornelles, LL Schiavon, LSC Mendes, ...
Hepatology International 19 (5), 1187-1198 , 2025
2025
Citations: 3
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
AT Ma, A Juanola, KR Patidar, A Barone, S Incicco, AV Kulkarni, N Verma, ...
Clinical Gastroenterology and Hepatology , 2025
2025
Citations: 3
MELD 3.0 PERFORMANCE: EXTERNAL VALIDATION IN A LATIN AMERICAN TRANSPLANT LIVER COHORT
JP Maronese, F Piñero, GC Narro, YIL Méndez, I Roca, N Dominguez, ...
Annals of Hepatology 30, 101954 , 2025
2025
Citations: 1
AMA-NEGATIVE PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: A DISTINCT SUBSET WITH LOWER TREATMENT RESPONSE
CA Couto, GGL Cançado, MLF Ferraz, DR Terrabuio, A Villamil, LC Solari, ...
Annals of Hepatology 30, 102013 , 2025
2025
EXPLORING THE ROLE OF METABOLIC DYSFUNCTION IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL STUDY
MIP Garayar, VC Gormaz, I Téllez, F Idalsoaga, G Im, B Alcayaga, ...
Annals of Hepatology 30, 101970 , 2025
2025
EARLY IDENTIFICATION OF LIVER TRANSPLANTATION REQUIREMENT IN ALCOHOL-ASSOCIATED HEPATITIS
LAD Piga, F Idalsoaga, G Im, B Alcayaga, M Haque, S Rutledge, H Blaney, ...
Annals of Hepatology 30, 101964 , 2025
2025
FIBRATES SEEM TO BE EQUALLY EFFECTIVE AS SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS, WITH BIOCHEMICAL RESPONSE PLATEAUING AT 6 MONTHS
GGL Cançado, ML Ferraz, DRB Terrabuio, A Villamil, LC Solari, ...
Annals of Hepatology 30, 102014 , 2025
2025
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis
J Trebicka, F Aguilar, A Queiroz Farias, JJ Lozano, C Sánchez-Garrido, ...
Gut 74 (8), 1293-1307 , 2025
2025
Citations: 21
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort …
KR Patidar, AT Ma, A Juanola, A Barone, S Incicco, A Kulkarni, ...
LANCET GASTROENTEROLOGY & HEPATOLOGY 10 (7), 9-9 , 2025
2025
Tu1507: MACHINE LEARNING IMPROVES MORTALITY PREDICTION IN A PROSPECTIVELY ENROLLED WORLDWIDE COHORT OF> 7700 PATIENTS HOSPITALIZED WITH CIRRHOSIS
A CHOUDHURY, Q Xie, M Topazian, PC Hayes, A Torre, H Desalegn, ...
Gastroenterology 169 (1), S-1434 , 2025
2025
TOP-217-YI Pathophysiological basis of acute on chronic liver failure (ACLF) triggered by alcohol-related hepatitis or infection using circulating biomarkers of inflammation …
J Pohl, A Kerbert, C de la Peña-Ramirez, C Sanchez, IW Zhang, ...
Journal of Hepatology 82, S132 , 2025
2025
FRI-185 Outpatient sbp prophylaxis associates with higher sbp reccurence in a global cohort of cirrhosis inpatients with greatest impact in high-income countries
J Bajaj, Q Xie, PS Kamath, M Topazian, P Hayes, A Torre, H Desalegn, ...
Journal of Hepatology 82, S141-S143 , 2025
2025
Evaluation of transient elastography and platelets count for predicting hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to …
P Guedes, J Piedade, H Perazzo, L Villela-Nogueira, H Peixoto, G Pereira, ...
Journal of Hepatology 82 , 2025
2025
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort …
KR Patidar, AT Ma, A Juanola, A Barone, S Incicco, AV Kulkarni, ...
The Lancet Gastroenterology & Hepatology 10 (5), 418-430 , 2025
2025
Citations: 14
Real-world practice patterns on the use of terlipressin in patients with cirrhosis and acute kidney injury-results from the ICA-GLOBAL AKI study
S Incicco, AT Ma, A Juanola, K Patidar, A Barone, A Kulkarni, ...
Digestive and Liver Disease 57, S9-S10 , 2025
2025
Citations: 1
Outpatient sbp prophylaxis associates with higher sbp reccurence in a global cohort of cirrhosis inpatients with greatest impact in high-income countries
J Bajaj, Q Xie, PS Kamath, M Topazian, P Hayes, A Torre, H Desalegn, ...
ELSEVIER , 2025
2025

MOST CITED SCHOLAR PUBLICATIONS

Prognostic importance of the cause of renal failure in patients with cirrhosis
M Martín–Llahí, M Guevara, A Torre, C Fagundes, T Restuccia, R Gilabert, ...
Gastroenterology 140 (2), 488-496. e4 , 2011
2011
Citations: 490
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis
C Fagundes, R Barreto, M Guevara, E Garcia, E Solà, E Rodríguez, ...
Journal of hepatology 59 (3), 474-481 , 2013
2013
Citations: 372
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
A Nazar, GH Pereira, M Guevara, M Martín‐Llahi, MN Pepin, M Marinelli, ...
Hepatology 51 (1), 219-226 , 2010
2010
Citations: 347
Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis
C Fagundes, MN Pépin, M Guevara, R Barreto, G Casals, E Solà, ...
Journal of hepatology 57 (2), 267-273 , 2012
2012
Citations: 312
Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis
J Altamirano, C Fagundes, M Dominguez, E García, J Michelena, ...
Clinical Gastroenterology and Hepatology 10 (1), 65-71. e3 , 2012
2012
Citations: 223
Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis
E Rodríguez, C Elia, E Solà, R Barreto, I Graupera, A Andrealli, G Pereira, ...
Journal of hepatology 60 (5), 955-961 , 2014
2014
Citations: 166
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension
E Sola, S Lens, M Guevara, M Martín‐Llahí, C Fagundes, G Pereira, ...
Hepatology 52 (5), 1783-1790 , 2010
2010
Citations: 139
Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy
M Guevara, ME Baccaro, B Gómez-Ansón, G Frisoni, C Testa, A Torre, ...
Journal of Hepatology 55 (3), 564-573 , 2011
2011
Citations: 128
Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy
M Guevara, ME Baccaro, B Gómez-Ansón, G Frisoni, C Testa, A Torre, ...
Journal of Hepatology 55, 564-573 , 2011
2011
Citations: 128
Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies
EC Castro Filho, R Castro, FF Fernandes, G Pereira, H Perazzo
Gastrointestinal endoscopy 92 (2), 440 , 2020
2020
Citations: 115
Type‐1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival
R Barreto, C Fagundes, M Guevara, E Sola, G Pereira, E Rodríguez, ...
Hepatology 59 (4), 1505-1513 , 2014
2014
Citations: 111
Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes
E Rodriguez, G Henrique Pereira, E Solà, C Elia, R Barreto, E Pose, ...
Liver Transplantation 21 (11), 1347-1354 , 2015
2015
Citations: 76
Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study
G Pereira, M Guevara, C Fagundes, E Solá, E Rodríguez, J Fernández, ...
Journal of hepatology 56 (5), 1040-1046 , 2012
2012
Citations: 70
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
S Muñoz-Martínez, V Sapena, A Forner, JC Nault, G Sapisochin, ...
JHEP reports 3 (3), 100260 , 2021
2021
Citations: 66
Procedural-related bleeding in hospitalized patients with liver disease (PROC-BLeeD): An international, prospective, multicenter observational study
NM Intagliata, RS Rahimi, F Higuera-de-la-Tijera, DA Simonetto, ...
Gastroenterology 165 (3), 717-732 , 2023
2023
Citations: 58
Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients
FF Fernandes, ML Ferraz, LE Andrade, A Dellavance, C Terra, G Pereira, ...
Journal of clinical gastroenterology 49 (3), 235-241 , 2015
2015
Citations: 57
Genetic ancestry, race, and severity of acutely decompensated cirrhosis in Latin America
AQ Farias, AC Vilalta, PM Zitelli, G Pereira, LL Goncalves, A Torre, ...
Gastroenterology 165 (3), 696-716 , 2023
2023
Citations: 44
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil
CM de Oliveira Lobato, L Codes, GF Silva, AFM Souza, HSM Coelho, ...
Annals of hepatology 18 (6), 849-854 , 2019
2019
Citations: 42
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
Z Cao, F Wong, AK Choudhury, PS Kamath, M Topazian, A Torre, ...
The Lancet Gastroenterology & Hepatology 9 (11), 997-1009 , 2024
2024
Citations: 41
Effectiveness of direct‐acting agents for hepatitis C and liver stiffness changing after sustained virological response
FF Fernandes, J Piedade, L Guimaraes, EP Nunes, U Chaves, ...
Journal of gastroenterology and hepatology 34 (12), 2187-2195 , 2019
2019
Citations: 34

GRANT DETAILS

Supervisor and principal mentor of FAPERJ-funded Scientific Initiation fellows, coordinating competitive undergraduate research projects in hepatology. Responsibilities include project conception, methodological supervision, manuscript preparation, and academic development of early-career researchers.

CONSULTANCY

Consulting and advisory roles in hepatology, cirrhosis management, and liver transplantation.

Industry, Institute, or Organisation Collaboration

Clinical and research collaboration with hepatology units, gastroenterology networks, and academic institutions in Brazil and abroad.

INDUSTRY EXPERIENCE

Medical consultant and speaker in hepatology and gastroenterology for educational and scientific activities.

SOCIAL, ECONOMIC, or ACADEMIC BENEFITS

Improvement of clinical pathways and diagnostic accuracy in liver diseases in public and private health systems; training of medical students and residents in hepatology.